LL-37 (Cathelicidin)，154947-66-7，合肥肽库生物

LL-37, human 是一种由37 个氨基酸残基组成的两亲性组织蛋白酶衍生的抗菌肽，具有广泛的抗菌活性。它有助于保护角膜免受感染，对于伤口愈合有着良好的促进作用，对多种革兰氏阳性和革兰氏阴性病原体具有抗菌和抗生物膜活性。

LL-37, human is a 37-residue, amphipathic, cathelicidin-derived antimicrobial peptide, which exhibits a broad spectrum of antimicrobial activity. LL-37, human could help protect the cornea from infection and modulates wound healing.

LL-37是一种具有血管生成活性的抗菌肽。它对应于人组织蛋白酶抗菌蛋白hCAP18/LL-37的C末端序列（134-170），并通过蛋白水解过程从hCAP18/LL-37细胞外释放。hCAP18/LL-37是先天免疫系统的效应器，在白细胞和上皮细胞中表达，与炎症和损伤相关上调。可以证明hCAP18/LL-37在一系列乳腺癌中的过表达。LL-37被认为部分通过甲酰肽受体样1（FPRL1）刺激上皮细胞增殖，因为用百日咳毒素阻断受体会使LL-37的增殖作用降低约50%。

LL-37 is an antimicrobial peptide with angiogenic activity. It corresponds to the C-terminal sequence (134-170) of the human cathelicidin antimicrobial protein hCAP18/LL-37 and is extracellularly released from hCAP18/LL-37 by proteolytic processing. hCAP18/LL-37 is an effector of the innate immune system and is expressed in leukocytes and epithelial cells where it is upregulated in association with inflammation and injury. An overexpression of hCAP18/LL-37 in a series of breast carcinomas could be demonstrated. LL-37 has been suggested to stimulate epithelial cell proliferation partially through formyl peptide receptor-like 1 (FPRL1) since blocking the receptor with pertussis toxin decreased the proliferative effect of LL-37 by approximately 50 %.

该产品由合肥肽库生物科技有限公司生产合成，合肥肽库生物专注科研多肽定制合成，以技术引领多肽科研